TD Asset Management’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-14,000
Closed -$260K 1197
2025
Q1
$260K Hold
14,000
﹤0.01% 1183
2024
Q4
$185K Sell
14,000
-48,000
-77% -$1.16M ﹤0.01% 1231
2024
Q3
$1.98M Buy
62,000
+24,200
+64% +$827K ﹤0.01% 1049
2024
Q2
$947K Buy
37,800
+15,200
+67% +$354K ﹤0.01% 1172
2024
Q1
$509K Sell
22,600
-8,800
-28% -$208K ﹤0.01% 1293
2023
Q4
$673K Hold
31,400
﹤0.01% 1259
2023
Q3
$564K Buy
+31,400
New +$599K ﹤0.01% 1252
2019
Q4
Sell
-19,122
Closed -$669K 1396
2019
Q3
$669K Sell
19,122
-3,022
-14% -$144K ﹤0.01% 1132
2019
Q2
$1.25M Buy
22,144
+1,635
+8% +$118K ﹤0.01% 1006
2019
Q1
$1.5M Buy
20,509
+6,400
+45% +$442K ﹤0.01% 967
2018
Q4
$900K Buy
14,109
+1,300
+10% +$96.7K ﹤0.01% 1082
2018
Q3
$1.28M Buy
12,809
+4,609
+56% +$382K ﹤0.01% 1101
2018
Q2
$583K Sell
8,200
-1,000
-11% -$83.9K ﹤0.01% 1237
2018
Q1
$958K Buy
9,200
+4,800
+109% +$541K ﹤0.01% 1073
2017
Q4
$443K Buy
+4,400
New +$324K ﹤0.01% 1208

Other funds holding ANAB

TD Asset Management's ANAB Position: Q2 2025 in Review

TD Asset Management sold out of AnaptysBio (ANAB) in Q2 2025, closing a stake of 14,000 shares — an estimated $260K sold.

TD Asset Management first reported a position in ANAB in Q4 2017 and held it in 15 quarters. The position peaked at $1.98M in Q3 2024. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

  • TD Asset Management reported no remaining AnaptysBio position as of Q2 2025 after selling out during the quarter.
  • TD Asset Management sold 14,000 AnaptysBio shares in Q2 2025, an estimated $260K.
  • TD Asset Management first reported a position in AnaptysBio in Q4 2017 and held it in 15 quarters.
  • TD Asset Management's AnaptysBio position peaked at $1.98M in Q3 2024.
  • 147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on TD Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.